US 11491125
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted A61KA61K31/197
Quick answer
US patent 11491125 (Baclofen formulations and methods of minimizing patient exposure to metabolite variations) held by AMNEAL PHARMACEUTICALS LLC expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Grant date
- Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/197